![](/img/cover-not-exists.png)
PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Faivre, S., Blanc, J.-F., Merle, P., Fasolo, A., Iacobellis, A., Grando, V., Decaens, T., Trojan, J., Villa, E., Stammberger, U., Bruns, R., Raymond, E.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw200.20
Date:
June, 2016
File:
PDF, 37 KB
english, 2016